Targeted drug raises hope for cervical cancer patients
New York: There's good news for patients suffering from cervical cancer, the second most common cancer in women.
In a clinical study, scientists have discovered that a drug erlotinib, a targeted anti-tumour agent, has potential to improve treatment for cervical cancer when combined with chemoradiation therapy.
The new treatment strategy involves targeting the epithelial growth factor receptor (EGFR), which is frequently over-expressed in cervical cancer.
Epidermal growth factor (EGF) stimulates the proliferation of a wide range of epidermal and epithelial cells. EGFR is a cell surface protein that binds to epidermal growth factor.
"While cervical cancer is a neglected disease and very few clinical trials have been reported in the last 10 years, some groups, including ours, have reported that its biology might be prone to targeted therapy," said Nogueira-Rodrigues of the Brazilian National Cancer Institute.
Nogueira-Rodrigues and her colleagues designed a phase 2 clinical trial to test the potential of the EFGR inhibitor erlotinib combined with chemoradiation therapy in 36 women with cervical cancer.
Median duration of therapy was 77 days and median follow-up time was 59.3 months.
The therapy was well tolerated overall, and 34 patients (94.4 percent) achieved a complete response, which means the disappearance of all cancerous lesions.
After three years, 80 percent of women were alive, and 73.8 percent experienced no disease progression.
"To the best of our knowledge, this is the first study to present that a targeted agent has promising activity in the management of locally advanced cervical disease," she said.
She added that targeted therapies may be added to the standard treatment for locally advanced cervical cancer if randomised trials confirm the current study results.
The study appeared in the journal CANCER, a peer-reviewed journal of the American Cancer Society.
More from India
More from World
More from Sports
More from Entertaiment
- Salman Khan attends sister Arpita's wedding reception in Mandi
- 2G scam: Ex-TRAI chief alleges Manmohan Singh had warned him to cooperate
- Zee Media's mega survey on Modi govt
- I eat beef, can somebody stop me?: Kiren Rijiju hits back at Naqvi
- Zee Media Exclusive: Vidya Balan chats about 'Hamari Adhuri Kahani'
- Delhi: Visually impaired boy scores 91.4% in CBSE 12th Board exams
- MP: 14-year-old boy works as bonded labour since 2009
- Smriti Irani visits Amethi, promises to pay insurance money to 25,000 women
- UP: Man chops off wife's nose, hair for dowry
- Zee Media Exclusive: The plight of yoga expert Tejaswi Sharma
- Woman denied flat in Mumbai for being a Muslim
- 4 Indians in Forbes' 100 most powerful women list
- BBV: What challenges lie ahead of Modi govt?
- DNA analysis of rising water crisis in India!
- Gujjar stir: HC asks Rajasthan govt to clear rail track, roads
- Arpita-Aayush wedding reception: Salman Khan spreads love in Mandi, says `hum aapke hain`
- CBSE Class 10 Board Result 2015 (cbse.nic.in, cbseresults.nic.in) postponed?
- CBSE Class 10 Board Result 2015 to be announced today
- Check mahresult.nic.in for MSBSHSE Maharashtra Class 12 HSC Result 2015
- Maharashtra MSBSHSE HSC Result 2015 on mahresult.nic.in
- MSBSHSE Class 12th HSC results 2015 to be declared at 1pm tomorrow
- Rahul Gandhi takes a dig at one year of Modi govt, wishes 'happy birthday' to 'suit-boot ki sarkar'
- I was misquoted, says Kiren Rijiju on 'beef' remark
- mahresult.nic.in updated with MSBSHSE Maharashtra HSC Class XII Result 2015
- First look: Salman Khan steals thunder in `Bajrangi Bhaijaan`
- CBSE 10th result to be declared tomorrow
- Check mahresult.nic.in for Maharashtra HSC Result 2015 to be announced at 1 pm on May 27
- Manmohan Singh defends himself on 2G charge, slams Modi govt for 'carbon copy' schemes
- Sonia Gandhi 'unconstitutional authority' during UPA: PM Narendra Modi
- Reservation stir: Five percent job quota to Gujjars unlikely, hints Rajasthan govt